Charu Aggarwal, MD, MPH

faculty photo
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
10-137, South Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-6318
Fax: 215-349-5326
Education:
MD
Lady Hardinge Medical College, New Delhi, India, 2003.
MPH (Health Care Organization and Policy)
University of Alabama at Birmingham, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Aggarwal is the Leslye Heisler Assistant Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principle investigator for multiple clinical trials focusing on the development of “targeted” immunotherapeutic approaches including cellular therapy and CAR-T for solid tumors. Dr. Aggarwal has led the development of a DNA plasmid based HPV specific immunotherapy for HPV associated head and neck cancers. She is actively involved in evaluating the role of plasma-based NGS in management of patients with metastatic lung cancer.

She has extensive experience in the planning, design and execution of clinical trials, is an active member of ECOG, and has served as a national sub-study chair for SWOG-NCI’s LUNG-MAP. She has served on the Annual Meeting Scientific Program Committee of American Society of Clinical Oncology (ASCO), ASCO Education Committee, NCI- Head and Neck Metastatic Task Force Steering Committee and ACC’s Data Safety and Monitoring Committee. Dr. Aggarwal’s ultimate goal as a clinical and translational investigator is to perform patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung and Head and Neck Cancer.

Selected Publications

Aggarwal C, Thompson JC, Carpenter EL.: Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response. Clinical Cancer Research 26 (13): 3492, Jul 2020 Notes: doi: 10.1158/1078-0432.CCR-20-1073.

Weinstein GS, Cohen R, Lin A, O'Malley BW Jr, Lukens J, Swisher-McClure S, Shanti RM, Newman JG, Parhar HS, Tasche K, Brody RM, Chalian A, Cannady S, Palmer JN, Adappa ND, Kohanski MA, Bauml J, Aggarwal C, Montone K, Livolsi V, Baloch ZW, Jalaly JB, Cooper K, Rajasekaran K, Loevner L, Rassekh C.: Penn Medicine Head and Neck Cancer Service Line COVID-19 Management Guidelines Head Neck 42(7): 1507-1515, Jul 2020.

Singh AP, Berman AT, Marmarelis ME, Haas AR, Feigenberg SJ, Braun J, Ciunci CA, Bauml JM, Cohen RB, Kucharczuk JC, Shulman LN, Langer CJ, Aggarwal C.: Management of Lung Cancer During the COVID-19 Pandemic Journal of Clinical Oncology - Oncology Practice Page: doi: 10.1200/OP.20.00286. May 2020.

Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA, Yee SS, Christensen T, LaRiviere MJ, Silva BA, Banks KC, Nagy RJ, Helman E, Berman AT, Ciunci CA, Singh AP, Wasser JS, Bauml JM, Langer CJ, Cohen RB, Carpenter EL: Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clinical Cancer Research Page: doi: 10.1158/1078-0432.CCR-19-3663, Feb 2020.

Jabbour SK, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB 2nd, Bradley JD, Aisner J, Malhotra J: Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncology Page: doi: 10.1001/jamaoncol.2019.6731, Feb 2020.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Cheung J, Dickerson K, Schulten V, Knoblock D, Gillespie E, Bauml JM, Yan J, Diehl M, Boyer J, Dallas M, Kim JJ, Weiner DB, Skolnik JM: Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. Vaccines (Basel) Jan 2020 Notes: 2020 Jan 29;8(1). pii: E56. doi: 10.3390/vaccines8010056.

Aggarwal C, Langer CJ: Systemic therapy for elderly patients with non–small cell lung cancer: Where do we stand in 2019? Cancer Jan 2020.

Swisher-McClure S, Lukens JN, Aggarwal C, Ahn P, Basu D, Bauml JM, Brody R, Chalian A, Cohen RB, Fotouhi-Ghiam A, Geiger G, Gershowitz J, Livolsi V, Mitra N, Montone K, Newman J, Ojerholm E, O'Malley B Jr, Rajasekaran K, Tan E, Weinstein G, Lin A: A Phase II Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed Following Transoral Robotic Surgery for Human Papilloma Virus Related Squamous Cell Carcinoma of the Oropharynx. Int J Radiat Oncol Biol Phys Page: pii: S0360-3016(19)34057-X, Nov 2019 Notes: doi: 10.1016/j.ijrobp.2019.11.021. [Epub ahead of print]

Gershowitz J, Chao HH, Doucette A, Lukens JN, Swisher-McClure S, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, Lin A: Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer. Br J Radiol doi: 10.1259/bjr.20190466, Oct 2019.

Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, Berman AT: Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC. Int J Radiat Oncol Biol Phys Page: pii: S0360-3016(19)33901-X, Oct 2019 Notes: doi: 10.1016/j.ijrobp.2019.10.019.

back to top
Last updated: 07/08/2020
The Trustees of the University of Pennsylvania